Cipla and ImmunoACT launch CAR‑T therapy in Africa

Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is India’s first indigenously developed anti‑CD19 CAR‑T therapy.

The exclusive license and supply agreement will see Cipla, through its subsidiary Medpro Pharmaceutica, commercialise the therapy in the Republic of South Africa, Algeria and Morocco. Furthermore, ImmunoACT will handle manufacturing.

A breakthrough in cancer treatment

Talicabtagene autoleucel is a cutting-edge autologous CAR‑T therapy designed to treat relapsed or refractory B‑cell Non‑Hodgkin’s Lymphoma (B‑NHL) and B‑cell Acute Lymphoblastic Leukemia (B‑ALL) in patients who have not responded to standard treatments. This therapy has already been administered to over 500 patients in India. It has demonstrated high efficacy, durable responses and a well-tolerated safety profile.

Expanding access to advanced cell therapy

This partnership aims to make advanced cell therapy more accessible and affordable in African markets with significant unmet medical needs. Cipla and ImmunoACT are addressing critical gaps in cancer care. They are doing this by reducing ancillary healthcare costs and offering a highly effective treatment option, .

Strategic collaboration for a healthier future

Achin Gupta, Cipla’s MD and global CEO designate, emphasised the importance of this partnership in strengthening Cipla’s oncology portfolio and advancing its mission to improve access to life-saving therapies.

Paul Miller, CEO of Cipla Africa, highlighted the potential of this collaboration to transform cancer care in the region. Dr Rahul Purwar, founder and chairman of ImmunoACT, expressed pride in bringing India’s indigenous CAR‑T therapy to a global stage.

A commitment to oncology innovation

This collaboration underscores Cipla’s dedication to innovation and its commitment to providing affordable healthcare solutions. By introducing talicabtagene autoleucel in Africa, Cipla and ImmunoACT are paving the way for a new era in cancer treatment.